ESTRO 2025 - Abstract Book

S1628

Clinical – äediatric tumours

ESTRO 2025

Conclusion: Re-irradiation can provide symptomatic relief and survival benefits, particularly in patients with prolonged time to relapse. However, further studies with larger cohorts are needed to better define its role and refine treatment protocols.

Keywords: Reirradiation, CNS

2138

Digital Poster Diffuse Intrinsic Pontine Glioma: Is reirradiation the only option for improved outcomes?

Cristina Morón Jiménez 1 , Andrea Denisse Gutiérrez Calderón 1 , Patricia Tavera Pomata 1 , Paula García-Abad Oviedo 1 , Marta Inés De la Cruz Rodríguez 1 , Ana Cecilia Navarrete Torres 1 , Andrés Camilo Moreno Moya 1 , Álvaro Lassaletta Atienza 2 , Elena Panizo Morgado 3 , Carmen González San Segundo 1 1 Radiation Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2 Pediatric Oncology, Hospital Universitario Niño Jesús, Madrid, Spain. 3 Paediatrics, Clínica Universidad de Navarra, Madrid, Spain Purpose/Objective: Diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive paediatric brain tumor with a grim prognosis. Despite advances in understanding its biology, treatments have had minimal impact on overall survival (OS). Standard treatment involves radiation therapy (RT), which improves symptoms and prolongs OS. Emerging strategies, including hypofractionated RT (hFRT) and re-irradiation (rRT), show promise in managing DIPG. This study evaluates the experience of a Spanish pediatric oncology center with RT in DIPG and compares it with findings from a national multicenter study.